Allogene Therapeutics Inc


Prices are adjusted according to historical splits.

Allogene Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$861.20 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Allogene Therapeutics Inc had its IPO on 2018-10-11 under the ticker symbol ALLO.

The company operates in the Healthcare sector and Biotechnology industry. Allogene Therapeutics Inc has a staff strength of 359 employees.

Stock update

Shares of Allogene Therapeutics Inc opened at $4.99 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $4.91 - $5.06, and closed at $5.02.

This is a -0.59% slip from the previous day's closing price.

A total volume of 1,323,310 shares were traded at the close of the day’s session.

In the last one week, shares of Allogene Therapeutics Inc have slipped by -8.89%.

Allogene Therapeutics Inc's Key Ratios

Allogene Therapeutics Inc has a market cap of $861.20 million, indicating a price to book ratio of 1.5084 and a price to sales ratio of 4133.631.

In the last 12-months Allogene Therapeutics Inc’s revenue was $243000 with a gross profit of $243000 and an EBITDA of $-321153984. The EBITDA ratio measures Allogene Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Allogene Therapeutics Inc’s operating margin was -138044.86% while its return on assets stood at -22.6% with a return of equity of -42.04%.

In Q3, Allogene Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 7.8%.

Allogene Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Allogene Therapeutics Inc’s profitability.

Allogene Therapeutics Inc stock is trading at a EV to sales ratio of 2674.7514 and a EV to EBITDA ratio of -2.2207. Its price to sales ratio in the trailing 12-months stood at 4133.631.

Allogene Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$887.57 million
Total Liabilities
$48.87 million
Operating Cash Flow
$24.91 million
Capital Expenditure
Dividend Payout Ratio

Allogene Therapeutics Inc ended 2023 with $887.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $887.57 million while shareholder equity stood at $739.96 million.

Allogene Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $48.87 million in other current liabilities, 144000.00 in common stock, $-1141133000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $74.36 million and cash and short-term investments were $552.23 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Allogene Therapeutics Inc’s total current assets stands at $569.06 million while long-term investments were $99.15 million and short-term investments were $477.87 million. Its net receivables were $9.38 million compared to accounts payable of $11.05 million and inventory worth $0.

In 2023, Allogene Therapeutics Inc's operating cash flow was $24.91 million while its capital expenditure stood at $223000.

Comparatively, Allogene Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Allogene Therapeutics Inc stock is currently trading at $5.02 per share. It touched a 52-week high of $17.49 and a 52-week low of $17.49. Analysts tracking the stock have a 12-month average target price of $22.69.

Its 50-day moving average was $6.61 and 200-day moving average was $9.99 The short ratio stood at 22.1 indicating a short percent outstanding of 0%.

Around 2971.8% of the company’s stock are held by insiders while 7903.5% are held by institutions.

Frequently Asked Questions About Allogene Therapeutics Inc

The stock symbol (also called stock or share ticker) of Allogene Therapeutics Inc is ALLO

The IPO of Allogene Therapeutics Inc took place on 2018-10-11

Similar Industry Stocks (Biotechnology)

Last Price
3i Group plc (TGOPF)
Xylem Inc (XYL)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.


210 East Grand Avenue, South San Francisco, CA, United States, 94080